Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, initially developed for lipid-lowering therapy in patients with hypercholesterolemia, were recently investigated for their potential role in cancer prevention [179]. Here, PCSK9 is linked to familial hypercholesterolemia.